ASTRO Issues Recs for Radiation Tx of Basal, Squamous Cell Carcinoma
RT recommended as primary treatment for BCC, cSCC patients who are not surgical candidates.
RT recommended as primary treatment for BCC, cSCC patients who are not surgical candidates.
Evidence reviewed for radiation therapy in adjuvant, neoadjuvant, definitive, and palliative settings.
A survey released by ASTRO, an industry trade group representing radiation oncologists, concluded that prior authorization serves as a barrier to prompt and effective patient care.
New joint guideline from ASTRO, ASCO, and AUA offers an alternative to conventional radiation regimens for those patients who opt for treatment instead of active surveillance or surgery.
[Breast Cancer: Targets and Therapy] In this retrospective analysis of medical records and estimated costs of treatment, investigators demonstrated that rapid change based on level I evidence is feasible.
Aggressive de-escalation of chemoradiation after surgery in patients with HPV-associated OPSCC led to similar disease control and improved quality of life and safety profile compared with historical controls, according to data presented at the ASTRO 59th Annual Meeting.
Palliative radiotherapy for bone metastases is safe, effective — but controversy persists for single-fraction treatment.
Qualifications to guidelines include stronger statements in favor of chemotherapy in some cases.
Shorter time to testosterone recovery with 18 versus 36 months androgen deprivation therapy.
The use of adjuvant radiation therapy in the treatment of endometrial cancer is detailed in a new guideline issued by the American Society of Radiation Oncology (ASTRO).